A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...
Por THE ASSOCIATED PRESSUna comisión reguladora europea rechazó el tratamiento de Eli Lilly contra la enfermedad de Alzheimer ...
Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...
Irish Examiner on MSN10h
Eli Lilly fails to get European approval for Alzheimer's drug KisunlaLilly will seek review of decision which said drug's benefits don’t outweigh risk of potentially fatal bleeding in the brain ...
A European health committee has rejected Eli Lilly’s Alzheimer’s drug, Kisunla, because of safety concerns about possible ...
Eli Lilly, which is seeking European approval of Kisunla for the treatment of early symptomatic Alzheimer's, said it will seek re-examination by CHMP. The Indianapolis drugmaker said it remains ...
Biogen and Eisai's Leqembi (lecanemab), the other beta-amyloid-targeting Alzheimer's drug on the market in the US, carries a similar warning, though patients in clinical trials seemed to experience ...
After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease ...
The European Medicines Agency committee declined to approve Eli Lilly's Alzheimer’s treatment, citing risks of brain bleeding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback